Models of dilated cardiomyopathy in the mouse and the hamster

Current Opinion in Cardiology

Volumn 15, Issue 3, 2000, Pages 197-201

  Ikeda, Yasuhiro ^a   Ross Jr , John ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALCIUM; CYTOKINE RECEPTOR; DYSTROPHIN; GLYCOPROTEIN GP 130; GUANINE NUCLEOTIDE BINDING PROTEIN; MYOSIN; TRANSCRIPTION FACTOR;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CYTOSKELETON; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; HAMSTER; HEART DILATATION; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM CHANNELS; CARDIOMYOPATHY, DILATED; CRICETINAE; CYTOSKELETON; DISEASE MODELS, ANIMAL; GTP-BINDING PROTEIN REGULATORS; HEART FAILURE, CONGESTIVE; HUMANS; MESOCRICETUS; MICE; MICE, TRANSGENIC; MUTATION; SARCOMERES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; VENTRICULAR DYSFUNCTION;

EID: 0034031341     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200005000-00013     Document Type: Review

References (57)

1. 1 McMinn TR Jr, Ross J Jr. Hereditary dilated cardiomyopathy. Clin Cardiol 1995, 18:7-15.
2. 2 Seidman CE, Seidman JG: Molecular genetics of inherited cardiomyopathies. In: Chien KR, ed. Molecular Basis of Cardiovascular Disease. Philadelphia: W.B. Saunders, 1999:251-263.
3. 3 Maron BJ: Hypertrophic cardiomyopathy [published erratum appears in Lancet 1997 Nov 1;350(9087):1330]. Lancet 1997, 350:127-133.
4. 4 Chien KR: Stress pathways and heart failure. Cell 1999, 98:555-558.
5. 5 Towbin JA: The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998, 10:131-139. Review of relations between cytoskeletal proteins and hereditary forms of human cardiomyopathy, including hypertrophic and dilated cardiomyopathies, as well as selected animal models.
6. 2, and others.
7. 7 Hongo M, Ryoke T, Ross JJ: Animal models of heart failure. Recent developments and perspectives. Trends Cardiovascular Med 1997, 7:161-167.
8. 8 Chen J, Chien KR: Complexity in simplicity: monogenic disorders and complex cardiomyopathies. J Clin Invest 1999, 103:1483-1485.
9. 9 Mogensen J, Klausen IC, Pedersen AK, et al.: Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103:R39-R43.
10. 10 Kumar A, Crawford K, Close L, et al.: Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin. Proc Natl Acad Sci USA 1997, 94:4406-4411.
11. 11 Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT: Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998, 280:750-752. First report describing a human heritable form of dilated cardiomyopathy caused by a mutation in α-cardiac actin involving its fixed end.
12. 12 McConnell BK, Jones KA, Fatkin D, et al.: Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999, 104:1235-1244.
13. 13 Sussman MA, Welch S, Cambon N, et al.: Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. J Clin Invest 1998, 101:51-61.
14. 14 Straub V, Campbell KP: Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 1997, 10:168-175. Review of the structure and putative function of all components of this complex.
15. 15 Melacini P, Fanin M, Duggan DJ, et al.: Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999, 22:473-479.
16. 16 Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR: Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997, 90:729-738.
17. 17 Megeney LA, Kablar B, Perry RL, Ying C, May L, Rudnicki MA: Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 1999. 96:220-225.
18. 18 Hack AA, Ly CT, Jiang F, et al.: Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J Cell Biol 1998, 142:1279-1287.
19. 19 Coral-Vazquez R, Cohn RD, Moore SA, et al.: Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999, 98:465-474.
20. 20 Arber S, Hunter JJ, Ross J, Jr, et al.: MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997, 88:393-403.
21. 21 Rockman HA, Chien KR, Choi DJ, et al.: Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998, 95:7000-7005.
22. 22 Minamisawa S, Hoshijima M, Chu G, et al.: Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999, 99:313-322. A report describing complete functional and histologic prevention of the DCM phenotype due to MLP knockout in the mouse by crossing with the phospholamban knockout mouse.
23. 23 Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 1996, 134:1255-1270.
24. 24 Li D, Tapscoft T, Gonzalez O, et al.: Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999, 100:461-464.
25. 25 Bonne G, Di Barletta MR, Varnous S, et al.: Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999, 21:285-288.
26. 26 Fatkin D, MacRae C, Sasaki T, Wolff MR, Seidman CE: Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction system disease. N Engl J Med 1999, 341:1715-1724.
27. 27 Shou W, Aghdasi B, Armstrong DL, et al.: Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 1998, 391:489-492.
28. 28 Jones LR, Suzuki YJ, Wang W, et al.: Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J Clin Invest 1998, 101:1385-1393.
29. 29 Molkentin JD, Lu JR, Antos CL, et al.: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
30. 30 Sussman MA, Lim HW, Gude N, et al.: Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998, 281:1690-1693.
31. 31 Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH: Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 1999, 84:729-734.
32. 32 Olson EN, Molkentin JD: Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? [see comments]. Circ Res 1999, 84:623-632. Interesting discussion of calcineurin-induced hypertrophy and its prevention by FK506 or cyclosporin in a variety of animal models.
33. 33 Shimoyama M, Hayashi D, Takimoto E, et al.: Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999, 100:2449-2454.
34. 34 D'Angelo DD, Sakata Y, Lorenz JN, et al.: Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 1997, 94:8121-8126.
35. 35 Adams JW, Sakata Y, Davis MG, et al.: Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998, 95:10140-10145. A transgenic mouse DCM model with severe, fatal DCM developing in association with apoptosis following pregnancy.
36. 36 Iwase M, Uechi M, Vatner DE, et al.: Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 1997, 272:H585-H589.
37. 1-adrenergic receptor. Circulation 1999, 100:1-762.
38. 1 receptor by tetracycline-controlled gene activation and deactivation (subsequently used to develop and reverse a DCM model [see text]).
39. 39 Hirota H, Yoshida K, Kishimoto T, Taga T: Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995, 92:4862-4866.
40. 40 Yoshida K, Taga T, Saito M, et al.: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996, 93:407-411.
41. 41 Hirota H, Chen J, Betz UA, et al.: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999, 97:189-198. A mouse with knockout of the GP130 gene using cre-loxP-based heart-specific technology in which rapidly developing DCM, heart failure, and apoptosis are produced by biomechanical stress.
42. 42 Hunter JJ, Rockman HA, Ross JJ: Models of cardiac disease in the mouse. In: Hoit BD, Walsh RA, eds. Cardiovascular Physiology in the Genetically Engineered Mouse. Dordrecht: Kluwer Academic Publishers Group, 1998:193-211. Review describing a variety of mouse models of hypertrophy and heart failure, including aortic banding and genetically engineered models, together with methods for in vivo physiologic and morphologic phenotyping.
43. 43 Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM: Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 1998, 101:2415-2426.
44. 44 DiMauro S, Hirano M: Mitochondria and heart disease. Curr Opin Cardiol 1998, 13:190-197.
45. 45 Wang J, Wilhelmsson H, Graff C, et al.: Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 1999, 21:133-137.
46. 46 Bajusz E, Baker JR, Nixon CW, Homburger F: Spontaneous, hereditary myocardial degeneration and congestive heart failure in a strain of Syrian hamsters. Ann NY Acad Sci 1969, 156:105-129.
47. 47 Ikeda Y, Martone M, Gu Y, et al.: Altered sarcolemmal permeability and membrane proteins correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol, in press.
48. 48 Ryoke T, YG, Mao L, et al.: Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation 1999, 100:1734-1743.
49. 49 Hunter EG, Hughes V, White J: Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. Canadian J Physiol Pharmacol 1984, 62:1423-1428.
50. 50 Nigro V, Okazaki Y, Belsito A, et al.: Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997, 6:601-607.
51. 51 Sakamoto A, Ono K, Abe M, et al.: Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997, 94:13873-13878.
52. 52 Sakamoto A, Abe M, Masaki T: Delineation of genomic deletion in cardiomyopathic hamster. FEBS Lett 1999, 447:124-128.
53. 53 Kawai C: From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999, 99:1091-1100. General review of role of viral myocarditis in causing dilated cardiomyopathy.
54. 54 Wessely R, Klingel K, Santana LF, et al.: Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest 1998, 102:1444-1453.
55. 55 Badorff C, Lee GH, Lamphear BJ, et al.: Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy [see comments]. Nat Med 1999, 5:320-326.
56. 56 Bachmaier K, Neu N, Yeung RS, Mak TW, Liu P, Penninger JM: Generation of humanized mice susceptible to peptide-induced inflammatory heart disease. Circulation 1999, 99:1885-1891.
57. 57 Patten RD, Aronovitz MJ, Deras-Mejia L, et al.: Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol 1998, 274:H1812-H1820.